• E Hasker, M Khodjikhanov, S Usarova, U Asamidinov, U Yuldashova, M J van der Werf, G Uzakova, and J Veen.
• Project HOPE, Tuberculosis Control Programme for the Central Asia Region, Tashkent, Uzbekistan. ehasker@itg.be
• Int. J. Tuberc. Lung Dis. 2009 Nov 1; 13 (11): 1405-10.

SettingUzbekistan has had 100% DOTS coverage since 2005; however, the treatment success rate has remained at around 80% for the last 4 years. Surveys from the capital city of Tashkent and from western Uzbekistan have shown high levels of primary multidrug resistance.ObjectiveTo assess treatment regimens prescribed for new cases of tuberculosis (TB), including the prescription of additional non-TB drugs, and the cost implications for the patient.DesignWe randomly sampled 30 clusters of seven new TB patients. Enrolled patients were interviewed and their medical records were reviewed.ResultsIn general, the treatment regimens prescribed were correct; doses were high rather than low. Second-line anti-tuberculosis drugs were rarely prescribed. In addition to anti-tuberculosis drugs, patients were prescribed on average seven to eight non-TB drugs. The rationale for prescribing the non-TB drugs was, however, questionable. Patients incurred substantial costs for these drugs, some of which were not without risk.ConclusionPrescriptions of anti-tuberculosis drugs for new TB patients are adequate; however, the practice of prescribing additional non-TB drugs needs to be reconsidered.

30 keywords...

hide…